Featured Press Releases

ViroCell Biologics Signs Master Services Agreement With Prominent NCI-Designated Cancer Center

ViroCell Biologics Signs Master Services Agreement With Prominent NCI-Designated Cancer Center

enGene’s Detalimogene Receives RMAT Designation from the FDA, Opening the Path for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

enGene’s Detalimogene Receives RMAT Designation from the FDA, Opening the Path for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

  • 25 Jun 2025

enGene Holdings Inc. a clinical-stage, non-viral gene-based immunotherapy company, announced that...

PCI Pharma Buys Ajinomoto Althea as Part of $1B Plan to Expand Injectable Drug Manufacturing in the U.S

PCI Pharma Buys Ajinomoto Althea as Part of $1B Plan to Expand Injectable Drug Manufacturing in the U.S

Xencor Announces Promising Early Results for XmAb942 in First-in-Human Study Targeting IBD

Xencor Announces Promising Early Results for XmAb942 in First-in-Human Study Targeting IBD

SK Life Science Labs Announces Nature Communications Publication of Breakthrough Molecular Glue Research Advancing Cancer Immunotherapy

SK Life Science Labs Announces Nature Communications Publication of Breakthrough Molecular Glue Research Advancing Cancer Immunotherapy

IRBM Expands Functional Genomics Platform for Early Drug Discovery

IRBM Expands Functional Genomics Platform for Early Drug Discovery

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

  • Spruce Biosciences, Inc.
  • 18 Aug 2025
Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

  • SystImmune, Inc.
  • 18 Aug 2025
New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

  • Genexa
  • 15 Aug 2025
Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

  • Daewoong Therapeutics Inc
  • 13 Aug 2025
Abcentra LLC Commences Phase 2b

Abcentra LLC Commences Phase 2b 'FORTIFY' Trial with First Patient Dosed, Evaluating Orticumab for Cardiovascular Disease

  • Abcentra
  • 12 Aug 2025
Viatris announces the approval of the first generic iron sucrose injection in the U.S

Viatris announces the approval of the first generic iron sucrose injection in the U.S

  • Viatris Inc.
  • 11 Aug 2025
Webinar: Leverage AI for Operational Excellence and Strategic Cost Management

Most Popular
August   2025
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.